The stabilization and membrane translocation of IRHOM2 mediated by palmitoylation can eventually accelerate the progression of non-alcoholic steatohepatitis (NASH) [96]. Here, RHBDF2 is linked to metabolic dysfunction-associated steatohepatitis.